Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CARsgen Therapeutics has announced that its autologous CAR T-cell product candidate, CT011, received Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) in China.
CARsgen successfully completed enrolment for a Phase I trial in China. Credit: Michal Jarmoluk from Pixabay.
Subscribe to our email newsletter
The IND clearance has been received for patients with GPC3-positive stage IIIa hepatocellular carcinoma at high risk of recurrence after surgical resection.
CT011 is designed to target Glypican-3 (GPC3), a protein associated with hepatocellular carcinoma (HCC).
CARsgen Therapeutics chief medical officer Raffaele Baffa said: “Hepatocellular carcinoma (HCC) stands as the predominant histologic subtype of primary liver cancer, ranking as the sixth most prevalent cancer type globally.
“We initially identified GPC3 as a viable target for CAR T-cell therapy and subsequently progressed it to clinical trials for the treatment of HCC. Case report has shown patients with advanced hepatocellular carcinoma have achieved disease-free survival for more than seven years. We will continue to explore the potential of CAR-T for solid tumors and bring new treatment options for patients.”
In 2019, the therapy obtained IND clearance from the NMPA to treat GPC3-positive solid tumours, becoming the first CAR T-cell therapy against solid tumours to achieve this in China.
Following this clearance, CARsgen successfully completed enrolment for a Phase I trial in the country.
Last year, CARsgen collaborated with Huadong Medicine to commercialise zevorcabtagene autoleucel (zevor-cel), CT053, in mainland China.
The fully human, autologous BCMA CAR T-cell product candidate of CARsgen, CT053 aims to treat relapsed/refractory multiple myeloma (R/R MM).
CARsgen has operations in the US and China and is focused on CAR T-cell therapies to treat haematologic malignancies as well as solid tumours.
